Oxyphenbutazone Anhydrous

CHEMBL1228 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

324.4 g/mol

LogP

2.7

Phase

4

An anhydrous form of oxyphenbutazone, sharing the same therapeutic uses.

Masse moléculaire

324,4000 g/mol

LogP

2,70

TPSA

60,90 Å²

Règle des 5 de Lipinski

Conforme

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O

InChI

InChI=1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3

Molecular Formula

C19H20N2O3

HBD / HBA

1 / 3

Liaisons Rotatives

5

Atomes Lourds

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

An anhydrous form of oxyphenbutazone, sharing the same therapeutic uses.

Yes, Oxyphenbutazone Anhydrous is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1228. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 4641. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Oxyphenbutazone Anhydrous sur PillFYI

Structure

Données Clés

Formule: C19H20N2O3

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.